Beta Bionics, Inc. $BBNX Stock Position Reduced by Bank of America Corp DE

Key Points

• Bank of America reduced its Beta Bionics position by 68.5% in the first quarter, selling 296,125 shares and retaining 136,215 shares worth approximately $1.37 million.
• Beta Bionics reported quarterly revenue of $32.01 million and an adjusted loss of $0.53 per share, which was better than analysts’ estimate of a $0.62 loss. The stock opened at $19.42, while its market capitalization stood at approximately $874 million.
• Analyst sentiment remains generally positive, with a “Moderate Buy” consensus and an average price target of $20.10, although price targets range widely. Several insiders also sold shares at about $19.11 each, primarily to cover tax obligations tied to vested equity awards.

Bank of America Corp DE decreased its position in Beta Bionics, Inc. (NASDAQ:BBNX - Free Report) by 68.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 136,215 shares of the company's stock after selling 296,125 shares during the quarter. Bank of America Corp DE owned 0.31% of Beta Bionics worth $1,365,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Charles Schwab Investment Management Inc. increased its position in Beta Bionics by 0.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 331,623 shares of the company's stock worth $10,105,000 after buying an additional 931 shares during the period. Deutsche Bank AG lifted its position in Beta Bionics by 3.4% in the fourth quarter. Deutsche Bank AG now owns 39,300 shares of the company's stock worth $1,197,000 after purchasing an additional 1,296 shares during the period. Summit Securities Group LLC acquired a new stake in Beta Bionics in the fourth quarter worth approximately $52,000. Caitong International Asset Management Co. Ltd boosted its stake in Beta Bionics by 1,075.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company's stock valued at $61,000 after purchasing an additional 1,818 shares in the last quarter. Finally, Verition Fund Management LLC boosted its stake in Beta Bionics by 4.0% during the 3rd quarter. Verition Fund Management LLC now owns 47,299 shares of the company's stock valued at $940,000 after purchasing an additional 1,823 shares in the last quarter.

Beta Bionics Trading Down 2.5%

NASDAQ BBNX opened at $19.42 on Friday. The firm's fifty day moving average price is $17.17 and its two-hundred day moving average price is $13.65. Beta Bionics, Inc. has a 1 year low of $8.80 and a 1 year high of $32.71. The firm has a market capitalization of $873.71 million, a P/E ratio of -11.77 and a beta of 3.37.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.09. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%.The firm had revenue of $32.01 million for the quarter. On average, research analysts anticipate that Beta Bionics, Inc. will post -2.1 EPS for the current fiscal year.

Insider Activity at Beta Bionics

In other Beta Bionics news, insider Mike Mensinger sold 4,375 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total value of $83,606.25. Following the transaction, the insider directly owned 180,040 shares of the company's stock, valued at $3,440,564.40. This represents a 2.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Steven Russell sold 4,221 shares of the firm's stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total transaction of $80,663.31. Following the sale, the insider owned 169,628 shares of the company's stock, valued at $3,241,591.08. This trade represents a 2.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 33,262 shares of company stock worth $604,002. 5.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Bank of America cut their target price on shares of Beta Bionics from $23.00 to $11.00 and set a "neutral" rating for the company in a research note on Monday, May 18th. The Goldman Sachs Group lifted their target price on Beta Bionics from $17.00 to $19.00 and gave the stock a "buy" rating in a report on Wednesday, July 15th. Weiss Ratings raised Beta Bionics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, August 18th. UBS Group assumed coverage on Beta Bionics in a report on Tuesday, July 28th. They set a "buy" rating and a $22.00 price objective on the stock. Finally, William Blair began coverage on shares of Beta Bionics in a report on Friday, August 21st. They set a "market perform" rating on the stock. Seven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Beta Bionics presently has an average rating of "Moderate Buy" and a consensus target price of $20.10.

Trending Headlines about Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Analyst sentiment remains favorable overall, with seven Buy ratings, four Holds and one Sell, producing a “Moderate Buy” consensus and an average price target of $20.10. Recent institutional purchases, including a new position by Bank of America valued at approximately $8.6 million, also provide some support. Beta Bionics insider trading and analyst coverage
• Neutral Sentiment: Several Beta Bionics insiders—including CFO Stephen Feider, Steven Russell, Mike Mensinger and Mark Hopman—sold shares at approximately $19.11 each. The transactions collectively involved about 20,600 shares, but the filings state the sales were made to cover tax-withholding obligations tied to vested equity awards, reducing their significance as a discretionary bearish signal. Beta Bionics insider sales
• Negative Sentiment: Schall, Brown & Schwartz LLP announced that it has filed a class-action lawsuit against Beta Bionics and is seeking investors to serve as lead plaintiffs. The litigation introduces potential legal costs, reputational risk and uncertainty regarding the company’s disclosures or conduct, creating the most significant near-term pressure on BBNX. The allegations have not been adjudicated. BBNX investor alert and class-action lawsuit

Beta Bionics Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company's flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics' offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.

Want to see what other hedge funds are holding BBNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Beta Bionics, Inc. (NASDAQ:BBNX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.